Trial reportSchizophrenia research2013
Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.
Trial report in Schizophrenia research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00884897 (Oxytocin and Social Cognition in Schizophrenia), which is not on this map. Cited by 37 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Oxytocin and Social Cognition in Schizophrenia
Who cites it
37 citing papers in PubMed, 5 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials.The international journal of neuropsychopharmacology · 2021Pooled it
- Chronic oxytocin administration as a tool for investigation and treatment: A cross-disciplinary systematic review.Neuroscience and biobehavioral reviews · 2020Pooled it
- Intranasal Oxytocin May Improve High-Level Social Cognition in Schizophrenia, But Not Social Cognition or Neurocognition in General: A Multilevel Bayesian Meta-analysis.Schizophrenia bulletin · 2017Pooled it
- Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.European archives of psychiatry and clinical neuroscience · 2016Pooled it
- RETRACTED: Effect of intranasal oxytocin administration on psychiatric symptoms: A meta-analysis of placebo-controlled studies.Psychiatry research · 2015Pooled it
- The effects of intranasal oxytocin on the efficacy of psychotherapy for major depressive disorder: a pilot randomized controlled trial.Psychological medicine · 2024Trial
- The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study.Schizophrenia research · 2017Trial
- A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.Journal of clinical psychopharmacology · 2017Trial
- Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia.Schizophrenia research · 2016Trial
- Effects of Oxytocin on Neural Response to Facial Expressions in Patients with Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- Oxytocin administration selectively improves olfactory detection thresholds for lyral in patients with schizophrenia.Psychoneuroendocrinology · 2015Trial
- Oxytocin administration enhances controlled social cognition in patients with schizophrenia.Psychoneuroendocrinology · 2014Trial
- Oxytocin-augmented social cognitive skills training in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Trial
- Translational pathways of oxytocin therapy in schizophrenia: bridging negative symptom domains and neural mechanisms.Translational psychiatry · 2026Review
- Intranasal Oxytocin Combined With Social Skills Training for Schizophrenia: An Add-on Randomized Controlled Trial.Schizophrenia bulletin open · 2024Article
- Oxytocin administration versus emotion training in healthy males: considerations for future research.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022Article
- Utility of Downstream Biomarkers to Assess and Optimize Intranasal Delivery of Oxytocin.Pharmaceutics · 2022Article
- Oxytocin-pathway polygenic scores for severe mental disorders and metabolic phenotypes in the UK Biobank.Translational psychiatry · 2021Article
- Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment.International journal of molecular sciences · 2021Review
- Intranasal oxytocin increases heart-rate variability in men at clinical high risk for psychosis: a proof-of-concept study.Translational psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundDeficits in olfactory identification have been widely reported in patients with schizophrenia (SZ) and are associated with negative symptomatology. Adjunctive oxytocin delivered intranasally has been shown to improve some aspects of social cognition as well as positive and negative symptoms in patients with schizophrenia. Given the intranasal delivery route of oxytocin to olfactory pathways and that olfactory abnormalities are a potential endophenotype in SZ, we investigated the effect of intranasal oxytocin on olfactory identification as well as positive and negative symptoms in people with schizophrenia.
methodsIndividuals with schizophrenia or schizoaffective disorder (n=28; 16 outpatients, 12 inpatients) were randomized to receive adjunctive intranasal oxytocin 20 IU BID or placebo for 3 weeks.
resultsAll 28 participants completed the clinical trial. Odor identification performance significantly improved on the University of Pennsylvania Smell Identification Test (UPSIT) total score and subscore for pleasant smells. UPSIT score (F=5.20, df=1,23, p=0.032) and subscore for pleasant smells (F=4.56, df=1,23, p=0.044), in patients treated with oxytocin were compared to placebo from baseline to endpoint. Global symptomatology as well as positive and negative symptoms were not improved by intranasal oxytocin. In fact, global symptoms, not positive or negative symptoms, improved in the placebo group. Secondary analysis shows that intranasal oxytocin improved negative symptoms in the small group of inpatients. Intranasal oxytocin was well tolerated during the three week trial.
conclusionAdjunctive intranasal oxytocin may improve olfactory identification, particularly in items of positive valence. Larger studies are needed to determine the effects of oxytocin on negative symptoms in SZ. (NCT00884897; http://www.clinicaltrials.gov).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.